Consequences of splice variation on Secretin family G protein‐coupled receptor function
暂无分享,去创建一个
[1] J. Tesmer,et al. Recognition in the Face of Diversity: Interactions of Heterotrimeric G proteins and G Protein-coupled Receptor (GPCR) Kinases with Activated GPCRs* , 2011, The Journal of Biological Chemistry.
[2] P. A. Friedman,et al. A Naturally Occurring Isoform Inhibits Parathyroid Hormone Receptor Trafficking and Signaling , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] H. Xu,et al. Structural Basis for Hormone Recognition by the Human CRFR2α G Protein-coupled Receptor* , 2010, The Journal of Biological Chemistry.
[4] L. Eiden,et al. PAC1hop receptor activation facilitates catecholamine secretion selectively through 2-APB-sensitive Ca(2+) channels in PC12 cells. , 2010, Cellular signalling.
[5] P. Sexton,et al. Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization , 2010, Regulatory Peptides.
[6] C. Koth,et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. , 2010, Structure.
[7] P. Sexton,et al. Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.
[8] A. Slominski,et al. Emerging role of alternative splicing of CRF1 receptor in CRF signaling. , 2010, Acta biochimica Polonica.
[9] A. Slominski,et al. Modulation of corticotropin releasing factor (CRF) signaling through receptor splicing in mouse pituitary cell line AtT-20--emerging role of soluble isoforms. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[10] A. Seasholtz,et al. Soluble corticotropin-releasing hormone receptor 2alpha splice variant is efficiently translated but not trafficked for secretion. , 2009, Endocrinology.
[11] Ruben Abagyan,et al. Functional Importance of a Structurally Distinct Homodimeric Complex of the Family B G Protein-Coupled Secretin Receptor , 2009, Molecular Pharmacology.
[12] A. Slominski,et al. CRF1 receptor splicing in epidermal keratinocytes: Potential biological role and environmental regulations , 2009, Journal of cellular physiology.
[13] H. Xu,et al. Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.
[14] H. Lehnert,et al. Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: lessons from the receptor variant R1d. , 2008, Molecular endocrinology.
[15] L. Miller,et al. Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. , 2008, Biochimica et biophysica acta.
[16] Sylvain Foissac,et al. A General Definition and Nomenclature for Alternative Splicing Events , 2008, PLoS Comput. Biol..
[17] Kjeld Madsen,et al. Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.
[18] H. Xu,et al. Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.
[19] M. Levine,et al. Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1beta and response to PKC phosphorylation. , 2008, Cellular signalling.
[20] N. Sultana,et al. Headless splice variant acting as dominant negative calcitonin receptor. , 2007, Biochemical and biophysical research communications.
[21] L. Miller,et al. Transmembrane Segment IV Contributes a Functionally Important Interface for Oligomerization of the Class II G Protein-coupled Secretin Receptor* , 2007, Journal of Biological Chemistry.
[22] Y. Takei,et al. Fish calcitonin receptor has novel features. , 2007, General and comparative endocrinology.
[23] R. Rudolph,et al. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor , 2007, Proceedings of the National Academy of Sciences.
[24] K. Mori,et al. Differential Intracellular Signaling through PAC1 Isoforms as a Result of Alternative Splicing in the First Extracellular Domain and the Third Intracellular Loop , 2007, Molecular Pharmacology.
[25] P. Hajduk,et al. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS , 2007, Proceedings of the National Academy of Sciences.
[26] R. Riek,et al. Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand , 2007, Proceedings of the National Academy of Sciences.
[27] L. Eiden,et al. The Hop Cassette of the PAC1 Receptor Confers Coupling to Ca2+ Elevation Required for Pituitary Adenylate Cyclase-activating Polypeptide-evoked Neurosecretion* , 2007, Journal of Biological Chemistry.
[28] H. Randeva,et al. Differential Responses of Corticotropin-Releasing Hormone Receptor Type 1 Variants to Protein Kinase C Phosphorylation , 2006, Journal of Pharmacology and Experimental Therapeutics.
[29] M. Johnson,et al. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: Consequences for signaling by VIP and PACAP , 2006, Molecular and Cellular Neuroscience.
[30] L. Miller,et al. Paired Cysteine Mutagenesis to Establish the Pattern of Disulfide Bonds in the Functional Intact Secretin Receptor* , 2005, Journal of Biological Chemistry.
[31] J. Vaughan,et al. A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[32] B. Wiesner,et al. Dimerization of Corticotropin-Releasing Factor Receptor Type 1 Is Not Coupled to Ligand Binding , 2005, Journal of receptor and signal transduction research.
[33] Charles E. Chapple,et al. Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype , 2004, Nature.
[34] J. Furkert,et al. Regulation of the Coupling to Different G Proteins of Rat Corticotropin-releasing Factor Receptor Type 1 in Human Embryonic Kidney 293 Cells* , 2004, Journal of Biological Chemistry.
[35] R. Riek,et al. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[36] H. Schiöth,et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.
[37] W. Fischer,et al. A Soluble Form of the First Extracellular Domain of Mouse Type 2β Corticotropin-releasing Factor Receptor Reveals Differential Ligand Specificity* , 2003, The Journal of Biological Chemistry.
[38] B. Wulff,et al. Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity , 2003, British journal of pharmacology.
[39] P. Sexton,et al. Novel Receptor Partners and Function of Receptor Activity-modifying Proteins* , 2003, The Journal of Biological Chemistry.
[40] L. Miller,et al. Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. , 2002, Cancer research.
[41] R. Rudolph,et al. In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. , 2002, Biophysical chemistry.
[42] L. Miller,et al. Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. , 2002, Gastroenterology.
[43] A. Slominski,et al. Alternative splicing of CRH‐R1 receptors in human and mouse skin: identification of new variants and their differential expression , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[44] W. Fischer,et al. Expression, Purification, and Characterization of a Soluble Form of the First Extracellular Domain of the Human Type 1 Corticotropin Releasing Factor Receptor* , 2001, The Journal of Biological Chemistry.
[45] J. Habener,et al. Novel Alternatively Spliced Exon in the Extracellular Ligand-binding Domain of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Type 1 Receptor (PAC1R) Selectively Increases Ligand Affinity and Alters Signal Transduction Coupling during Spermatogenesis* , 2001, The Journal of Biological Chemistry.
[46] A. Evdokiou,et al. Sustained activation of Erk1/2 MAPK and cell growth suppression by the insert-negative, but not the insert-positive isoform of the human calcitonin receptor. , 2000, The Journal of endocrinology.
[47] R. Rudolph,et al. The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. , 2000, Biochemistry.
[48] R. Hauger,et al. N‐Terminal Splice Variants of the Type I PACAP Receptor: Isolation, Characterization and Ligand Binding/Selectivity Determinants , 1999, Journal of neuroendocrinology.
[49] Gavin Kilpatrick,et al. Human CRF2 α and β splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay , 1999, Neuropharmacology.
[50] Gavin Kilpatrick,et al. Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. , 1999, Neuropharmacology.
[51] B. Largent,et al. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. , 1998, Molecular endocrinology.
[52] P. Sexton,et al. Function of the rat calcitonin receptors, C1a and C1b, expressed in Xenopus oocytes. , 1998, Biochemical and biophysical research communications.
[53] C. Montrose‐Rafizadeh,et al. High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor* , 1997, The Journal of Biological Chemistry.
[54] R. Pederson,et al. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. , 1997, Endocrinology.
[55] T. Usdin,et al. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. , 1996, The Journal of clinical investigation.
[56] T. Moody,et al. Differential Signaling and Immediate‐Early Gene Activation by Four Splice Variants of the Human Pituitary Adenylate CyclaseActivating Polypeptide Receptor (hPACAP‐R) , 1996, Annals of the New York Academy of Sciences.
[57] S. Goldring,et al. Full Activation of Chimeric Receptors by Hybrids between Parathyroid Hormone and Calcitonin , 1996, The Journal of Biological Chemistry.
[58] Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): Effect of a GIP-specific receptor antagonist , 1996, Regulatory Peptides.
[59] P. Sexton,et al. Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. , 1995, Molecular endocrinology.
[60] C. Nabhan,et al. The alternatively spliced type II corticotropin-releasing factor receptor, stably expressed in LLCPK-1 cells, is not well coupled to the G protein(s). , 1995, Biochemical and biophysical research communications.
[61] L. Miller,et al. Critical Contributions of Amino-terminal Extracellular Domains in Agonist Binding and Activation of Secretin and Vasoactive Intestinal Polypeptide Receptors. STUDIES OF CHIMERIC RECEPTORS (*) , 1995, The Journal of Biological Chemistry.
[62] M. Gershengorn,et al. Alternative splicing of a 48-nucleotide exon generates two isoforms of the human calcitonin receptor. , 1995, Endocrinology.
[63] A. Abou-Samra,et al. Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor. , 1995, Endocrinology.
[64] F. Holsboer,et al. Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. , 1995, Biochemical Society transactions.
[65] T. Serwold,et al. Chimeric human calcitonin and glucagon receptors reveal two dissociable calcitonin interaction sites. , 1995, Biochemistry.
[66] T. V. Ramabhadran,et al. A variant of the human corticotropin-releasing factor (CRF) receptor: cloning, expression and pharmacology. , 1994, Biochemical and biophysical research communications.
[67] P. Sexton,et al. Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction. , 1994, Endocrinology.
[68] K. Lewis,et al. Expression cloning of a human corticotropin-releasing-factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[69] Laurent Journot,et al. Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.
[70] K. Beaumont,et al. Molecular cloning of two receptors from rat brain with high affinity for salmon calcitonin , 1993, FEBS letters.
[71] P. Sexton,et al. Identification of brain isoforms of the rat calcitonin receptor. , 1993, Molecular endocrinology.
[72] H. Lodish,et al. Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. , 1992, The Journal of clinical investigation.
[73] F. Cardinaux,et al. N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo. , 1992, Biochemical and biophysical research communications.
[74] T. Rink,et al. 8–37h‐CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo , 1991, FEBS letters.
[75] M. Chorev,et al. A new highly potent parathyroid hormone antagonist: [D-Trp12,Tyr34]bPTH-(7-34)NH2. , 1988, Endocrinology.
[76] J. T. Turner,et al. A fragment of vasoactive intestinal peptide, VIP(10–28), is an antagonist of VIP in the colon carcinoma cell line, HT29 , 1986, Peptides.